---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-24-000043"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:37:31.027284+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q2 net loss $53.4M; INPEFA sales $1.6M; ZYNQUISTA NDA resubmitted

## Summary
- Net loss $53.4M ($0.17/sh) vs $44.9M a year ago; cash & investments $310M, up from $170M.
- INPEFA (sotagliflozin) net sales $1.6M; commercial launch ongoing.
- NDA for ZYNQUISTA in type 1 diabetes resubmitted; PDUFA goal date Dec 20, 2024.
- SONATA Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy commenced.
- PROGRESS Phase 2b (LX9211) for DPNP topline data expected Q2 2025.

## SEC filing metadata
- accession: 0001062822-24-000043
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000043/0001062822-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000043/lxrx-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-24-000043
- JSON: https://secwatch.observer/filing/0001062822-24-000043.json
- Plain text: https://secwatch.observer/filing/0001062822-24-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.